Literature DB >> 11572954

AKT plays a central role in tumorigenesis.

J R Testa1, A Bellacosa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11572954      PMCID： PMC58668          DOI： 10.1073/pnas.211430998

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  50 in total

1.  Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily.

Authors:  P F Jones; T Jakubowicz; F J Pitossi; F Maurer; B A Hemmings
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

2.  Akt activation by growth factors is a multiple-step process: the role of the PH domain.

Authors:  A Bellacosa; T O Chan; N N Ahmed; K Datta; S Malstrom; D Stokoe; F McCormick; J Feng; P Tsichlis
Journal:  Oncogene       Date:  1998-07-23       Impact factor: 9.867

3.  Pleckstrin domain homology.

Authors:  R J Haslam; H B Koide; B A Hemmings
Journal:  Nature       Date:  1993-05-27       Impact factor: 49.962

4.  Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families.

Authors:  P J Coffer; J R Woodgett
Journal:  Eur J Biochem       Date:  1991-10-15

5.  Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway.

Authors:  R C Muise-Helmericks; H L Grimes; A Bellacosa; S E Malstrom; P N Tsichlis; N Rosen
Journal:  J Biol Chem       Date:  1998-11-06       Impact factor: 5.157

6.  AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.

Authors:  J Q Cheng; A K Godwin; A Bellacosa; T Taguchi; T F Franke; T C Hamilton; P N Tsichlis; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

7.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.

Authors:  D A Cross; D R Alessi; P Cohen; M Andjelkovich; B A Hemmings
Journal:  Nature       Date:  1995 Dec 21-28       Impact factor: 49.962

Review 8.  Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation.

Authors:  P J Coffer; J Jin; J R Woodgett
Journal:  Biochem J       Date:  1998-10-01       Impact factor: 3.857

9.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.

Authors:  A Bellacosa; D de Feo; A K Godwin; D W Bell; J Q Cheng; D A Altomare; M Wan; L Dubeau; G Scambia; V Masciullo; G Ferrandina; P Benedetti Panici; S Mancuso; G Neri; J R Testa
Journal:  Int J Cancer       Date:  1995-08-22       Impact factor: 7.396

10.  The proteins encoded by c-akt and v-akt differ in post-translational modification, subcellular localization and oncogenic potential.

Authors:  N N Ahmed; T F Franke; A Bellacosa; K Datta; M E Gonzalez-Portal; T Taguchi; J R Testa; P N Tsichlis
Journal:  Oncogene       Date:  1993-07       Impact factor: 9.867
View more
  258 in total

1.  Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.

Authors:  Li-E Wang; Hongxia Ma; Katherine S Hale; Ming Yin; Larissa A Meyer; Hongliang Liu; Jie Li; Karen H Lu; Bryan T Hennessy; Xuesong Li; Margaret R Spitz; Qingyi Wei; Gordon B Mills
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-07       Impact factor: 4.553

2.  Novel adapter protein AP162 connects a sialyl-Le(x)-positive mucin with an apoptotic signal transduction pathway.

Authors:  S Hartel-Schenk; A Gratchev; M L Hanski; D Ogorek; G Trendelenburg; M Hummel; M Höpfner; H Scherübl; M Zeitz; C Hanski
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

3.  Protein kinase B/Akt binds and phosphorylates PED/PEA-15, stabilizing its antiapoptotic action.

Authors:  Alessandra Trencia; Anna Perfetti; Angela Cassese; Giovanni Vigliotta; Claudia Miele; Francesco Oriente; Stefania Santopietro; Ferdinando Giacco; Gerolama Condorelli; Pietro Formisano; Francesco Beguinot
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

4.  Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice.

Authors:  Gianluigi Condorelli; Alessandra Drusco; Giorgio Stassi; Alfonso Bellacosa; Roberta Roncarati; Guido Iaccarino; Matteo A Russo; Yusu Gu; Nancy Dalton; Clarence Chung; Michael V G Latronico; Claudio Napoli; Junichi Sadoshima; Carlo M Croce; John Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-17       Impact factor: 11.205

5.  Akt/PKB interacts with the histone H3 methyltransferase SETDB1 and coordinates to silence gene expression.

Authors:  Haidong Gao; Zhigang Yu; Dongsong Bi; Liyu Jiang; Yazhou Cui; Jingzhong Sun; Rong Ma
Journal:  Mol Cell Biochem       Date:  2007-06-19       Impact factor: 3.396

6.  Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?

Authors:  Teresa Troiani; Erika Martinelli; Floriana Morgillo; Anna Capasso; Anna Nappi; Vincenzo Sforza; Fortunato Ciardiello
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

7.  Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis.

Authors:  Yong Liao; Mien-Chie Hung
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

8.  Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis.

Authors:  Piotr G Rychahou; JungHee Kang; Pat Gulhati; Hung Q Doan; L Andy Chen; Shu-Yuan Xiao; Dai H Chung; B Mark Evers
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

9.  Selection of more aggressive variants of the gI101A human breast cancer cell line: a model for analyzing the metastatic phenotype of breast cancer.

Authors:  Dina Chelouche Lev; Galina Kiriakova; Janet E Price
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

Review 10.  Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.

Authors:  Zeynep Eroglu; Tomoko Tagawa; George Somlo
Journal:  Oncologist       Date:  2014-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.